> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Neurocrine's Product Sales Top $1 Billion In A Quarter For The First Time, And Ingrezza Outlook Rises
- URL: https://www.bullished.co/neurocrines-product-sales-top-1-billion-in-a-quarter-for-the-first-time-and-ingrezza-27d7732d/
- Published: 2026-11-02T21:23:20.000Z
- Updated: 2026-11-02T21:23:20.000Z
- Description: Third-quarter revenue grew 41% to $1.1 billion on Crenessity and Vykat XR, while profit under standard accounting dipped to $207 million.
- Author: Matteo Parrino
- Tags: Earnings, NBIX, Industry: Healthcare

[Neurocrine Biosciences](https://www.bullished.co/tag/nbix/), the San Diego drugmaker behind Ingrezza, [reported third-quarter revenue of $1.1 billion](https://www.sec.gov/Archives/edgar/data/0000914475/000091447526000053/q3-2026xearningsrelease.htm?ref=bullished.co), up 41% from $795 million a year earlier, and said quarterly net product sales passed $1 billion for the first time. The company also raised its full-year Ingrezza sales guidance to $2.9 billion to $2.925 billion, in an [8-K filed Monday](https://www.sec.gov/Archives/edgar/data/0000914475/000091447526000053/nbix-20261102.htm?ref=bullished.co).

## Three drugs carry the quarter

Ingrezza, which treats tardive dyskinesia and chorea associated with Huntington's disease, brought in $801 million, up 17% from $687 million. The company cited double-digit volume growth and record prescription counts.

Crenessity, for classic congenital adrenal hyperplasia, a rare hormone disorder, more than doubled to $211 million from $98 million, up 115%. About 80% of dispensed prescriptions won reimbursement, the company said.

Vykat XR, the Prader-Willi syndrome drug Neurocrine gained through its purchase of Soleno Therapeutics, which closed in May, added $107 million. It had no sales in the year-earlier quarter.

CEO Kyle Gano said the results reflect "strong underlying demand across our diversified portfolio of first-in-class medicines."

## Adjusted profit up, reported profit down

Net income under standard accounting slipped to $207 million, or $1.96 a share, from $210 million, or $2.04\. The quarter carried a $52 million loss on the fair value of equity investments, against a $31 million gain a year earlier, plus Soleno-related expenses and a larger amortization charge on acquired assets.

On an adjusted basis, net income rose to $347 million, or $3.29 a share, from $222 million, or $2.17\. Higher net product sales of $329 million drove the comparison, the company said.

Neurocrine's balance sheet recorded about $2.2 billion of Vykat XR intellectual property, which it will amortize over 16 years. Amortization of acquired intangibles was $35 million in the quarter, versus $1 million a year ago.

## Cash drops after the Soleno deal

The company's results table shows cash, cash equivalents and marketable securities of about $790 million at September 30, against $2,543 million at December 31, 2025\. The condensed balance sheet lists a narrower line of $737.9 million against $1,480.4 million, with noncurrent marketable securities listed separately.

Looking ahead, Gano pointed to Phase 3 readouts for osavampator in major depressive disorder and direclidine in schizophrenia among the clinical milestones he sees in 2027\. Neurocrine also named Eiry Roberts, previously its chief medical officer and most recently a strategic advisor, as chief medical officer again.

Neurocrine holds an R&D Day in New York on December 15, 2026.

Learn

- [Item 2.02: results of operations →](https://www.bullished.co/learn/8-k-items-explained/#item-202-results-of-operations)  
From 8-K Items Explained: What Every Item Code From 1.01 To 9.01 Tells You, With Examples

### Sources

- [8-K Filing — NEUROCRINE BIOSCIENCES INC (NBIX)](https://www.sec.gov/Archives/edgar/data/0000914475/000091447526000053/nbix-20261102.htm?ref=bullished.co) — SEC EDGAR
- [Exhibit q3-2026xearningsrelease.htm — NEUROCRINE BIOSCIENCES INC 8-K exhibit](https://www.sec.gov/Archives/edgar/data/0000914475/000091447526000053/q3-2026xearningsrelease.htm?ref=bullished.co) — SEC EDGAR
- [Nxera Pharma Operational Highlights and Consolidated Results for the Third Quarter 2026](https://uk.finance.yahoo.com/news/nxera-pharma-operational-highlights-consolidated-063500136.html?ref=bullished.co) — Yahoo Finance
- [Nxera Pharma Operational Highlights and Consolidated](https://www.globenewswire.com/news-release/2026/10/30/3392032/0/en/nxera-pharma-operational-highlights-and-consolidated-results-for-the-third-quarter-2026.html?ref=bullished.co) — globenewswire.com

### More on Neurocrine Biosciences

- [Vanguard Portfolio Management Reports 5% Passive Stake In Neurocrine Biosciences](https://www.bullished.co/vanguard-portfolio-management-reports-5-passive-stake-in-neurocrine-biosciences-ef0bebad/)

[All Neurocrine Biosciences (NBIX) coverage →](https://www.bullished.co/tag/nbix/)